EP2501384
METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
Anmelder
NOVARTIS AG [CH]
Erfinder
GALLAGHER NEIL [CH]YIN OPHELIA [US]
Externe Quellen
Klassifikation
IPC-Klassen
A61K 31/506A61K 9/00A61P 35/00C07D 239/69
CPC-Klassen
A61K 31/506A61K 9/0095A61P 11/00A61P 11/06A61P 17/00A61P 17/06A61P 19/02A61P 19/04A61P 25/00A61P 25/28A61P 29/00A61P 35/00A61P 35/02A61P 37/06A61P 43/00A61P 9/12C07D 239/69
AI: Life Sciences
warum
Novartis oncology pharma — A61K + A61P35 + C07D239. Life Science.